Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

NCT01668641 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: GLPG0634
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV